20/20 Biolabs, Inc. Common Stock (AIDX)vsMerck & Company Inc (MRK)
AIDX
20/20 Biolabs, Inc. Common Stock
$0.55
+5.86%
HEALTHCARE · Cap: $5.60M
MRK
Merck & Company Inc
$135.84
+0.21%
HEALTHCARE · Cap: $316.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3565141% more annual revenue ($65.77B vs $1.84M). MRK leads profitability with a 13.6% profit margin vs -279.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).
AIDX
Avoid21
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
-60.9%
Fair Value
$81.38
Current Price
$135.84
$54.46 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -354.6% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
ROE of 7.6% — below average capital efficiency
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Price/Book.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
AIDX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.21 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?